Many States See Potential in the Idea
The Bank of North Dakota, the only state-owned bank operating in the United States, primarily aims to promote agriculture, commerce and industry, and to stimulate economic development through several lending programs. Unlike infrastructure banks that operate more as finance authorities, the Bank of North Dakota is a depository institution. And unlike other financial institutions, the state bank is not F.D.I.C. insured; its deposits instead are guaranteed by the full faith and credit of the state of North Dakota. With 12 bills introduced in 2013, other states could decide to follow the path that North Dakotas legislature took in 1919. Proponents of state-owned banks argue that they create new jobs and encourage broader economic growth by providing more loans to small businesses at a time when commercial financial lending is limited. State-owned banks generate revenue for states without raising taxes (through the banks dividends) and may offer affordable alternatives for public infrastructure projects at lower borrowing costs. Proponents also contend that these institutions strengthen local banks by acting as a bankers bank, lending to commercial financial institutions. Critics counter that state-owned banks require significant start-up capital from public coffers and could disrupt the economy because they would withdraw the public funds now held by large commercial banks. Because there would be no F.D.I.C. insurance, these institutions pose a risk to states in the event of any bank losses. Critics also assert that state-owned banks are unnecessary because commercial financial institutions already lend to qualified borrowers meaning a state-owned bank would unfairly compete against commercial banks. State lawmakers have been weighing the options. Since 2010, legislators in 22 states have introduced bills either to study the issue or to create a state-owned bank or investment trust.
Teva’s Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management’s current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialize additional pharmaceutical products, including our ability to develop, manufacture, market and sell biopharmaceutical products, competition for our innovative products, especially COPAXONE(R) (including competition from innovative orally-administered alternatives, as well as from potential purported generic equivalents), competition for our generic products (including from other pharmaceutical companies and as a result of increased governmental pricing pressures), competition for our specialty pharmaceutical businesses, our ability to achieve expected results through our specialty, including innovative, R&D efforts, the effectiveness of our patents and other protections for innovative products, decreasing opportunities to obtain U.S. market exclusivity for significant new generic products, our ability to identify, consummate and successfully integrate acquisitions, the effects of increased leverage as a result of recent acquisitions, the extent to which any manufacturing or quality control problems damage our reputation for high quality production and require costly remediation, our potential exposure to product liability claims to the extent not covered by insurance, increased government scrutiny in both the U.S. and Europe of our agreements with brand companies, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, our exposure to currency fluctuations and restrictions as well as credit risks, the effects of reforms in healthcare regulation and pharmaceutical pricing and reimbursement, any failures to comply with complex Medicare and Medicaid reporting and payment obligations, governmental investigations into sales and marketing practices (particularly for our specialty pharmaceutical products), uncertainties surrounding the legislative and regulatory pathways for the registration and approval of biotechnology based products, adverse effects of political or economical instability, corruption, major hostilities or acts of terrorism on our significant worldwide operations, interruptions in our supply chain or problems with our information technology systems that adversely affect our complex manufacturing processes, any failure to retain key personnel or to attract additional executive and managerial talent, the impact of continuing consolidation of our distributors and customers, variations in patent laws that may adversely affect our ability to manufacture our products in the most efficient manner, potentially significant impairments of intangible assets and goodwill, potential increases in tax liabilities, the termination or expiration of governmental programs or tax benefits, environmental risks and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31, 2012 and in our other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update or revise any forward looking statement, whether as a result of new information, future events or otherwise. SOURCE: Teva Pharmaceutical Industries Ltd. Teva Pharmaceutical Industries Ltd.
Teva Announces Launch of Generic Zemplar(R) in the United States
team. Previous Presidents Cup appearances: 1996, 2007, 2009, 2011 Presidents Cup record: 11-8-0 World Ranking: 28 PGA Tour victories: 5 A captain’s pick for the Presidents Cup two years ago, Haas earned automatic selection for this week on the way to a very consistent 2013 PGA Tour season that included a nine top-10s. Won the fifth title of his career on the U.S, circuit at the AT&T National in June and is expected to be paired up with his good friend Webb Simpson at Muirfield Village. Previous Presidents Cup appearances: 2011 Presidents Cup record: 1-3-1 World Ranking: 26 PGA Tour victories: 5 Often a wild card selection for U.S. teams, Mahan was an automatic choice for Muirfield Village after another successful PGA Tour campaign, especially in the bigger events. He recorded top-10s at the U.S. Open and British Open and was runner-up at the WGC-Accenture Match Play Championship, which he won in 2012. Has greatly improved his short game over the past two years. Previous Presidents Cup appearances: 2007, 2009, 2011 Presidents Cup record: 8-5-1 World Ranking: 11 PGA Tour victories: 10 Johnson clinched an automatic place on the U.S. team in spectacular style, sinking a 26-foot birdie putt on the final hole of the Deutsche Bank Championship. He then underlined his form by winning his 10th title on the PGA Tour with a two-shot victory at the weather-delayed BMW Championship. A very steady player with a brilliant short game who excels at matchplay.